November 14, 2014 – Today is World Diabetes Day. Globally, 382 million people were living with diabetes in 2013. In 2035, it is estimated that 592 million people will be living with diabetes, a 55% increase from today1.

In sub-Saharan Africa, non-communicable diseases like diabetes are on the rise2. However, many African countries are ill-prepared to deal with these new healthcare challenges2.

In Ethiopia, Sandoz has initiated a new project called Sandoz Executive Medical Management Academy (SEMMA), an educational program for …

Pneumonia kills 1 million children each year. Amoxicillin is the #1 treatment for childhood pneumonia. Sandoz holds the leading position in antibiotics and amoxicillin is one of our top ten products worldwide.

world-pneumonia-day

In June 2014, Sandoz committed to the world’s …

  • Sandoz launches new ready to use oral formulation of ACC® in the Ukrainian market
  • ACC® oral solution is used for children from 2 years old
  • New form has cherry flavor and is available with convenient dispenser

Kiev, November 12, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.

ACC® oral solution (active substance acetylcysteine) is used to treat acute and chronic bronchopulmonary diseases when it is necessary to reduce …

Princeton, New Jersey, November 10, 2014 – Sandoz today announced the US market introduction of cyclophosphamide injection, USP.

Sandoz is launching cyclophosphamide injection, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).

Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It is also used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children. New cases of leukemia, …

  • Regulatory authorities in Estonia, Latvia and Lithuania grant marketing authorizations for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, November 4, 2014 – Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). …

November 03, 2014 – Today the RAND Corporation projected that the introduction of biosimilar drugs in the US will reduce direct spending on biologics by USD 44.2 billion from 2014 to 2024. Currently there are no biosimilars approved by the FDA for use in the US. Products submitted for review by FDA through the Biologics Price Competition and Innovation Act pathway are developed with highly similar quality, safety and efficacy to marketed biologics, but they come at a lower price. A biosimilar will be approved if …

Basel, October 28, 2014 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company.”

  • Net sales up 4% (+5% cc)1 in Q3, with operating margin increase across Q3 and 9M
    • Net sales of USD 14.7 billion grew 4% (+5% cc2) in Q3
    • Strong …
  • Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team
  • Pneumonia is the leading cause of infectious death globally among children under five, killing 1 million children each year and amoxicillin is the #1 treatment for childhood pneumonia

Holzkirchen, October 23, 2014 – Sandoz today announces the delivery of 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to the United Nations (UN). This follows Sandoz’ commitment to the UN Every Newborn Action Plan, launched in June …

  • Sandoz delivers 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to UN and joins UN Pneumonia Innovations Team
  • Pneumonia is the leading cause of infectious death globally among children under five, killing 1 million children each year and amoxicillin is the #1 treatment for childhood pneumonia

Holzkirchen, October 23, 2014 – Sandoz today announces the delivery of 100,000 packs of amoxicillin 250mg dispersible tablets (DT) to the United Nations (UN). This follows Sandoz’ commitment to the UN Every Newborn Action Plan, launched in June …

October 15, 2014 – Today is International Day of Rural Women, established by the United Nations to bring awareness to the critical contribution rural women make to improving living conditions worldwide. For rural women, health issues such as pregnancy complications are significantly compounded by limited availability of knowledgeable medical staff. Two new global reports confirm the vital role midwives can play in dramatically reducing maternal and newborn death.